{
    "nctId": "NCT00280930",
    "briefTitle": "Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer",
    "officialTitle": "A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density",
    "overallStatus": "UNKNOWN",
    "conditions": "Post-Menopausal, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "To determine the proportion of women with breast density of > grade 4 who have a decrease in breast density of at least one grade after treatment with letrozole for one year.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal status defined as: women \\>55 years of age-no spontaneous menses for at least 12 months; in women \\< 55 years-no spontaneous menses within the past 12 months and with an FSH level \\>34.4 IU/I; bilateral oophorectomy\n* If subject had prior invasive breast cancer it must have been surgically removed at the time of orginal diagnosis with no evidence of metastases and the primary tumor may be receptive negative, positive or equivocal\n* Baseline mammogram (within 6 months) indicating mammographic density occupying \\>25% (grade 4/5, 5/6 or 6/6) of the breast tissue\n* Baseline breast examination demonstrating no clinical evidence of breast cancer\n* Acceptable quality DEXA of the L2-L4 postero-anterior (PA) spine and hup must be performed 6 months of randomization\n* Subject is willing and able to complete the quality of life questionnaire in either English or French\n\nExclusion Criteria:\n\n* Mammogram suspicious for breast cancer (unless subsequently ruled out)\n* Patient's with prior malignancies are eligible unless they have metastatic disease\n* Uncontrolled metabolic or endocrine disease, cardiovascular disease or malabsorption syndrome\n* Current chemotherapy or immunotherapy\n* Hormone replacement therapy or Evista (raloxifene) discontinued less than three months before baseline mammogram\n* Tamoxifen therapy discontinued less than six months prior to randomization",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}